S. Perez-Gutthann

First name
Last name
Margulis, A. V., Linder, M., Arana, A., Pottegard, A., Berglind, I. A., Bui, C. L., et al. (2018). Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. PLoS One. http://doi.org/10.1371/journal.pone.0204456
Cainzos-Achirica, M., Varas-Lorenzo, C., Pottegard, A., Asmar, J., Plana, E., Rasmussen, L., et al. (2018). Methodological challenges when evaluating potential off-label prescribing of drugs using electronic health care databases: A case study of dabigatran etexilate in Europe. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4416
Rebordosa, C., Plana, E., Aguado, J., Thomas, S., Garcia-Gil, E., Perez-Gutthann, S., & Castellsague, J. (2018). GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD). Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4448
Castellsague, J., Kuiper, J. G., Pottegard, A., Berglind, A., Dedman, D., Gutierrez, L., et al. (2018). A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). Clin Epidemiol. http://doi.org/10.2147/clep.s146442
Rebordosa, C., Aguado, J., Plana, E., Thomas, S., Frances, A., Lei, A., et al. (2019). Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom. Respir Med. http://doi.org/10.1016/j.rmed.2019.04.018
Arana, A., Margulis, A. V., Varas-Lorenzo, C., Bui, C. L., Gilsenan, A., McQuay, L. J., et al. (2020). Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5150
Phiri, K., Hallas, J., Linder, M., Margulis, A., Suehs, B., Arana, A., et al. (2021). A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Curr Med Res Opin. http://doi.org/10.1080/03007995.2021.1891035
Arana, A., Pottegard, A., Kuiper, J. G., Booth, H., Reutfors, J., Calingaert, B., et al. (2021). Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clinical Epidemiology. http://doi.org/https://doi.org/10.2147/CLEP.S331287
Hoffman, V., Hallas, J., Linder, M., Margulis, A. V., Suehs, B. T., Arana, A., et al. (2021). Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-021-01095-7
Rebordosa, C., Plana, E., Rubino, A., Aguado, J., Lei, A., Daoud, S., et al. (2021). A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink. Int J Chron Obstruct Pulmon Dis. http://doi.org/10.2147/copd.s301624